‘We are delighted that the data out of this Phase 2 trial support plazomicin’s potential utility as an important new treatment choice for patients with certain critical Gram-negative bacterial infections,’ said Kenneth J. Hillan, M.B. Ch.B., LEADER Chief and Officer Medical Officer of Achaogen. ‘We intend to consult with the FDA relating to the design of future research with plazomicin, which we intend to initiate in the first half of 2013. Our objective is to conduct innovative studies that would evaluate plazomicin’s effectiveness in treating seriously ill sufferers for whom available treatments are ineffective currently.’ Achaogen, Inc.READ ON >> 8. Vortioxetine and ticagrelor At the end of July, the FDA warned health care professionals and individuals that name misunderstandings between the antidepressant Brintellix and the bloodstream thinner Brilinta have triggered dispensing and prescribing errors. Health care professionals can decrease the risk of brand name confusion by like the generic name—vortioxetine for Brintellix and ticagrelor for Brilinta—as well as the intended indication when prescribing these medicines. Meanwhile, patients should examine their prescriptions to make sure that the right drug was dispensed. Institute for Safe Medication Practices president Michael Cohen, RPh, MS, ScD, DPS, FASHP, previously recognized the Brintellix and Brilinta misunderstandings among the the majority of common name-related medication protection issues reported to ISMP this past year.